Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s Why These Five Stocks Are on the Move Today

Page 1 of 2

All three major indexes are in the green as Deutsche Bank AG (USA) (NYSE:DB) worries fade. Shares of the German investment bank are up over 12% on news of a potential settlement, helping other financial stocks do well. Throw in the fact that many energy stocks are also up, and it’s not hard to see the market closing the third quarter with a good showing.

In this article, we will analyze five stocks that are on the move today, Emergent Biosolutions Inc (NYSE:EBS), Vectrus Inc (NYSE:VEC), Cognizant Technology Solutions Corp (NASDAQ:CTSH), Delcath Systems, Inc. (NASDAQ:DCTH), and Nova Lifestyle Inc (NASDAQ:NVFY). In addition, we will see how the smart money is positioned towards each stock.

Through extensive research, we determined that imitating some of the picks of hedge funds and other institutional investors can help generate market-beating returns over the long run. The key is to focus on the small-cap picks of these investors, since they are usually less followed by the broader market and are less price-efficient. Our backtests that covered the period between 1999 and 2012, showed that following the 15 most popular small-caps among hedge funds can help a retail investor beat the market by an average of 95 basis points per month (see the details here).

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research


Emergent Biosolutions Inc (NYSE:EBS) shares are 12% in the green after the company provided an update on the status of its 2011 BioThrax procurement contract due to expire today. According to the company, the CDC has exercised an option to procure all remaining BioTrax doses, and thereby committed to take delivery of the full 44.75 million doses spelled out under the contract. Emergent is also in ‘active negotiations’ with the CDC with respect to a follow-on procurement contract that hasn’t yet been finalized. Also today, Emergent announced that it had signed a multi-year contract with the Biomedical Advanced Research and Development Authority for the advanced development and delivery of an anthrax vaccine candidate, NuThrax. The contract consists of a five year base period of performance valued at around $200 million to develop NuThrax and procurement options for the company to potentially realize up to $1.4 billion in sales more depending on the deliveries. The company anticipates the FDA could authorize NuThrax for emergency use as early as 2018. Jim Simons’ Renaissance Technologies raised its stake in Emergent Biosolutions Inc (NYSE:EBS) by 15% in the second quarter to 1.27 million shares held at the end of June.

Follow Emergent Biosolutions Inc. (NYSE:EBS)
Trade (NYSE:EBS) Now!

Vectrus Inc (NYSE:VEC) shares have retreated by over 45% after the company disclosed that the U.S. government did not select its contract proposal to provide comprehensive support services for all U.S. Army facilities in Kuwait. Vectrus is currently the incumbent contractor providing these services, and its contract runs through December 28 before expiring. According to our data, the number of funds with holdings in Vectrus Inc (NYSE:VEC) rose by one quarter-over-quarter to 13 at the end of June.

Follow Vectrus Inc. (LON:VEC)
Trade (LON:VEC) Now!

On the next page, we will examine why traders are buying and selling Cognizant Technology Solutions Corp, Delcath Systems, and Nova Lifestyle.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!